192 related articles for article (PubMed ID: 23110259)
1. Axitinib, a new therapeutic option in renal cell carcinoma.
Kessler ER; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2012 Oct; 48(10):633-44. PubMed ID: 23110259
[TBL] [Abstract][Full Text] [Related]
2. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
3. Axitinib for the treatment of metastatic renal cell carcinoma.
Parekh H; Griswold J; Rini B
Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
[TBL] [Abstract][Full Text] [Related]
4. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C; Lau C; Josephson DY; Pal SK
Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
[TBL] [Abstract][Full Text] [Related]
6. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
[TBL] [Abstract][Full Text] [Related]
7. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
8. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
[TBL] [Abstract][Full Text] [Related]
9. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
10. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
11. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
12. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
[TBL] [Abstract][Full Text] [Related]
13. Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.
Payton S
Nat Rev Urol; 2013 Jun; 10(6):308. PubMed ID: 23649292
[No Abstract] [Full Text] [Related]
14. Axitinib-induced acute pancreatitis: a case report.
Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
17. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
18. Kidney cancer: progress and controversies in neoadjuvant therapy.
Posadas EM; Figlin RA
Nat Rev Urol; 2014 May; 11(5):254-5. PubMed ID: 24752207
[TBL] [Abstract][Full Text] [Related]
19. SU11248 and AG013736: current data and future trials in renal cell carcinoma.
Rini BI
Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985
[TBL] [Abstract][Full Text] [Related]
20. Axitinib (Inlyta) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
[No Abstract] [Full Text] [Related]
[Next] [New Search]
